NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!
Track your stocks, dividends, monitor DRIP shares, and project your passive income.
Start Free »

IQV | NYSE

$269.65 $0.00 | 0.00%

Next Earnings: Sep 15, 2026

Company Overview:

Market Cap: $0
Trailing PE: 0x
FWD PE *: 19.8x
Payout Ratio (TTM):
52-Week Range: $154.50 - $272.35

* Forward PE is based on street estimates.

10 Year IQV Performance Metrics:

Total Return (with DRIP): 246.4% (13.23% CAGR)
Total Return (no DRIP): 246.4% (13.23% CAGR)
Share Price: 246.4% (13.23% CAGR)
Yield on Cost (with DRIP):
Total Invested: $10,000
Total Value (with DRIP): $34,637
Total Return $ (with DRIP): $24,637
IQV Total Return
1Y 2Y 5Y 10Y All
IQV Price Chart
1Y 2Y 5Y 10Y All
DRIPCalc.com
IQV Price

Unlock All Reports & Research Dividend Stocks.

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)

IQV Earnings, Revenue, Cash & Debt, Shares Outstanding:

IQV - Revenue
IQV Revenue CAGR:1Y: 8.74%2Y: 7.02%5Y: 4.90%10Y: 10.90%
IQV - Earnings Per Share (EPS)
IQV EPS CAGR:1Y: -0.65%2Y: -11.87%5Y: 11.20%10Y: 7.98%
IQV - Net Income
🔒 Unlock
IQV Net Income CAGR:1Y: -3.01%2Y: -15.69%5Y: 8.07%10Y: 11.61%
IQV - EBITDA
🔒 Unlock
IQV EBITDA CAGR:1Y: 9.60%2Y: 2.36%5Y: 5.24%10Y: 15.00%
IQV - Free Cash Flow
🔒 Unlock
IQV Free Cash Flow CAGR:1Y: 23.29%2Y: -10.06%5Y: -1.79%10Y: 43.92%
IQV - Free Cash Flow / Share
🔒 Unlock
IQV Free Cash Flow / Share CAGR:1Y: 26.68%2Y: -6.11%5Y: 0.92%10Y: 39.16%
IQV - Operating Income
🔒 Unlock
IQV Operating Income CAGR:1Y: 12.45%2Y: 4.61%5Y: 14.75%10Y: 14.21%
IQV - Gross Profit
🔒 Unlock
IQV Gross Profit CAGR:1Y: 8.47%2Y: 4.03%5Y: 5.18%10Y: 12.90%
IQV - Shares Outstanding
🔒 Unlock
IQV Shares Outstanding CAGR:1Y: -3.41%2Y: -4.72%5Y: -3.01%10Y: 3.25%
IQV - Share Buybacks
🔒 Unlock
IQV Share Buybacks CAGR:1Y: -39.42%2Y: 0.00%5Y: 54.64%10Y: 0.00%
IQV - Stock-Based Comp
🔒 Unlock
IQV Stock-Based Comp CAGR:1Y: 58.33%2Y: 40.68%5Y: 14.63%10Y: 25.15%
IQV - Expenses
🔒 Unlock
IQV Expenses CAGR:1Y: 31.13%2Y: 17.67%5Y: 6.43%10Y: 20.31%
IQV - Revenue vs Net Income
🔒 Unlock
IQV - EPS vs FCF / Share
🔒 Unlock
IQV - EPS vs PE Ratio
🔒 Unlock
IQV - FCF vs FCF / Share
🔒 Unlock
IQV - FCF vs Stock Based Comp
🔒 Unlock
IQV - Cash & Debt
🔒 Unlock
IQV - Revenue by Segment
🔒 Unlock
IQV Revenue CAGR:1Y: 8.74%2Y: 7.02%5Y: 4.90%10Y: 10.90%
IQV - Revenue by Region
🔒 Unlock
IQV Revenue CAGR:1Y: 8.74%2Y: 7.02%5Y: 4.90%10Y: 10.90%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

IQV - REVENUE: Actual + Estimates
🔒 Unlock
IQV Actual Revenue CAGR:1Y: 8.74%2Y: 7.02%5Y: 4.90%10Y: 10.90%
IQV - EPS: Actual + Estimates
🔒 Unlock
IQV Actual EPS CAGR:1Y: -0.65%2Y: -11.87%5Y: 11.20%10Y: 7.98%
IQV - NET INCOME: Actual + Estimates
🔒 Unlock
IQV Actual Net Income CAGR:1Y: -3.01%2Y: -15.69%5Y: 8.07%10Y: 11.61%
IQV - EBITDA: Actual + Estimates
🔒 Unlock
IQV Actual EBITDA CAGR:1Y: 9.60%2Y: 2.36%5Y: 5.24%10Y: 15.00%

Ratios, Profit Margins & Return on Capital:

IQV - Net Profit Margin
🔒 Unlock
IQV Net Profit Margin CAGR:1Y: -11.48%2Y: -21.54%5Y: 2.86%10Y: 0.47%
IQV - Gross Profit Margin
🔒 Unlock
IQV Gross Profit Margin CAGR:1Y: -0.27%2Y: -2.80%5Y: 0.26%10Y: 1.81%
IQV - Price to Earnings
🔒 Unlock
IQV - Price To Sales Ratio
🔒 Unlock
IQV - Return on Capital Employed
🔒 Unlock
IQV - Return on Invested Capital
🔒 Unlock

Compare stocks side-by-side
 

Projected Future Returns & Dividends for IQV

Based on past 10-year performance, here are IQV growth metrics:

Share price CAGR of +13.23%
Dividend CAGR of +0%

Using IQV CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, is modelled to grow as follows:

IQV (DRIP)IQV - No DRIP
Current Price$269.65$269.65
Start Shares37.0937.09
Start Value$10,000$10,000
  
After 10 years:
Final Share Count37.0937.09
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$269.65$269.65
Total Dividends$0$0
Final Value$10,000$10,000

Estimated Future Value + Dividends - IQV

NOTE: Above numbers are our estimate based on IQV's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)

Company Info

IQVIA Holdings Inc. (IQV) had its IPO on 2013-05-09, and is trader on NYSE stock exchange.

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

IQV website: https://www.iqvia.com


Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)